![Cureus | Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity? | Article Cureus | Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity? | Article](https://assets.cureus.com/uploads/figure/file/32276/article_river_571cc1602cc211e8b9426fdb8651bcaa-picture-1.v1.png)
Cureus | Hyperpigmentation with Capecitabine: Part of Hand-Foot Syndrome or a Separate Entity? | Article
![Molecules | Free Full-Text | Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review Molecules | Free Full-Text | Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review](https://pub.mdpi-res.com/molecules/molecules-13-01897/article_deploy/html/images/molecules-13-01897-g001.png?1568812910)
Molecules | Free Full-Text | Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
![Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously](https://www.spandidos-publications.com/article_images/ol/3/6/OL-03-06-1191-g00.jpg)
Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously
![Low-Dose Xeloda After Surgery for Triple-Negative Breast Cancer Reduces Recurrence Risk - CancerConnect Low-Dose Xeloda After Surgery for Triple-Negative Breast Cancer Reduces Recurrence Risk - CancerConnect](https://news.cancerconnect.com/.image/ar_1:1%2Cc_fill%2Ccs_srgb%2Cg_xy_center%2Cq_auto:good%2Cw_1200%2Cx_958%2Cy_348/MTc5OTc1MDg4NzM1MDAzNzcw/image-placeholder-title.png)
Low-Dose Xeloda After Surgery for Triple-Negative Breast Cancer Reduces Recurrence Risk - CancerConnect
![Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®) - ScienceDirect Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1462388904000535-gr5.jpg)